NCT06028932 2026-03-05A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer PatientsYale UniversityPhase 2 Active not recruiting20 enrolled
NCT06040970 2025-12-02Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial CancerIcahn School of Medicine at Mount SinaiPhase 1/2 Recruiting54 enrolled
NCT03992131 2024-01-16A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)pharmaand GmbHPhase 1/2 Terminated25 enrolled 11 charts